sr 27897 has been researched along with Neuroblastoma in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bachy, A; Bignon, E; Boigegrain, R; Brodin, R; Cottineau, M; Gully, D; Herbert, JM; Keane, P; Labie, C; Le Fur, G; Maffrand, JP; Molimard, JC; Olliero, D; Oury-Donat, F; Pascal, M; Petereau, C; Prabonnaud, V; Rockstroh, MP; Schaeffer, P; Servant, O; Soubrié, P; Thurneyssen, O | 1 |
1 other study(ies) available for sr 27897 and Neuroblastoma
| Article | Year |
|---|---|
SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. I. In vitro studies.
Topics: 3T3 Cells; Animals; Calcium; Calcium-Calmodulin-Dependent Protein Kinases; CHO Cells; Cricetinae; Devazepide; DNA-Binding Proteins; Early Growth Response Protein 1; Genes, Immediate-Early; Hormone Antagonists; Humans; Immediate-Early Proteins; Indoleacetic Acids; Indoles; Inosine Monophosphate; Mice; Neuroblastoma; Receptor, Cholecystokinin A; Receptor, Cholecystokinin B; Receptors, Cholecystokinin; Recombinant Proteins; Sincalide; Thiazoles; Transcription Factors; Tumor Cells, Cultured | 1999 |